In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

How do you follow a genuine drug breakthrough, a cure for hepatitis C? Andrew McConaghie visits Gilead's headquarters near San Francisco to hear how the company plans to sustain its huge success.

After revenues flattened in the first three months of the year, in the second quarter Gilead saw its total sales fall 6%, largely down to shrinking revenues from its HCV portfolio. Sales shrunk in ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it had ...

The HIV and hepatitis C drugmaker's shares have seen an increase ... The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share ...